-
Je něco špatně v tomto záznamu ?
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
CK. Negi, P. Babica, L. Bajard, J. Bienertova-Vasku, G. Tarantino
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- antioxidancia terapeutické užití MeSH
- játra metabolismus MeSH
- lidé MeSH
- nealkoholová steatóza jater farmakoterapie metabolismus MeSH
- racionální návrh léčiv MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. With no Food and Drug Administration approved drugs, current treatment options include dietary restrictions and lifestyle modification. NAFLD is closely associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. Hence, clinically various pharmacological approaches using existing drugs such as antidiabetic, anti-obesity, antioxidants, and cytoprotective agents have been considered in the management of NAFLD and nonalcoholic steatohepatitis (NASH). However, several pharmacological therapies aiming to alleviate NAFLD-NASH are currently being examined at various phases of clinical trials. Emerging data from these studies with drugs targeting diverse molecular mechanisms show promising outcomes. This review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms. In addition, we also discuss the importance and utility of new approach methodologies and regulatory perspectives for NAFLD-NASH drug development.
Department of Pathological Physiology Faculty of Medicine Masaryk University Brno Czech Republic
RECETOX Faculty of Science Masaryk University Kotlarska 2 Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22002994
- 003
- CZ-PrNML
- 005
- 20220127150741.0
- 007
- ta
- 008
- 220113s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.metabol.2021.154925 $2 doi
- 035 __
- $a (PubMed)34740573
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Negi, Chander K $u RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno, Czech Republic
- 245 10
- $a Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease / $c CK. Negi, P. Babica, L. Bajard, J. Bienertova-Vasku, G. Tarantino
- 520 9_
- $a Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. With no Food and Drug Administration approved drugs, current treatment options include dietary restrictions and lifestyle modification. NAFLD is closely associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. Hence, clinically various pharmacological approaches using existing drugs such as antidiabetic, anti-obesity, antioxidants, and cytoprotective agents have been considered in the management of NAFLD and nonalcoholic steatohepatitis (NASH). However, several pharmacological therapies aiming to alleviate NAFLD-NASH are currently being examined at various phases of clinical trials. Emerging data from these studies with drugs targeting diverse molecular mechanisms show promising outcomes. This review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms. In addition, we also discuss the importance and utility of new approach methodologies and regulatory perspectives for NAFLD-NASH drug development.
- 650 _2
- $a antioxidancia $x terapeutické užití $7 D000975
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a játra $x metabolismus $7 D008099
- 650 _2
- $a nealkoholová steatóza jater $x farmakoterapie $x metabolismus $7 D065626
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Babica, Pavel $u RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno, Czech Republic. Electronic address: pavel.babica@recetox.muni.cz
- 700 1_
- $a Bajard, Lola $u RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno, Czech Republic
- 700 1_
- $a Bienertova-Vasku, Julie $u RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Tarantino, Giovanni $u Department of Clinical Medicine and Surgery, Federico II University Medical School of Naples, Naples, Italy
- 773 0_
- $w MED00010225 $t Metabolism: clinical and experimental $x 1532-8600 $g Roč. 126, č. - (2022), s. 154925
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34740573 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127150737 $b ABA008
- 999 __
- $a ok $b bmc $g 1750697 $s 1154143
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 126 $c - $d 154925 $e 20211102 $i 1532-8600 $m Metabolism, clinical and experimental $n Metabolism $x MED00010225
- LZP __
- $a Pubmed-20220113
